Wen Moon

Just a curious person who will listen to your favorite songs.

[Wen Moon @rojasanne]

thank me later bud @CoobyHo @eugene34812322 @FiguratiCo @Anthony_bee_ @Haytham44793298 @JODxAK @bdallhm21971252

[Wen Moon @rojasanne]

instant C💰A💰S💰H @n1tNc1DEHecSUuh @dalong818 @KingNFTPromoter @charlie_defi @akuwangi_Crypto @sad_mach1n3 @juangonzalezdev @moeltixdotcom @FurnWu @rohitku44281958 @MaziNzelum @bootiemonsta @yzaneo @IntenseRealism @elhadaddii27 @cptbalao @PeterOr42021920

[Wen Moon @rojasanne]

If one of you get in I need 30%🤪 @Ansorie0 @cheomedicen @samchik16 @IgorAlexPereir2 @bambaiwalla @Eugene911_32755 @infernoshh @RackroV @katanyabwin @iampbiswal @sparklingbigwin @Nii_Boye_Amarh

[Wen Moon @rojasanne]

Post storm sunset @lakelaniercom @FOX5Atlanta

[Wen Moon @rojasanne]

The Chasing M's Foundation Community Toy Drive
https://t.co/nFsllJAHgY

[ClinicalXchange @ClinicalXchange]

Don't miss 10/26/22 webinar on #SCLC, #ImmunoOncology in Untreated ES-SCLC, Treatment Approaches in Prev. Treated ES-SCLC & Key Clinical Trials in LS- & ES-SCLC. Details & free reg.: https://t.co/IHd0SJIcNG @HopkinsMedicine @hopkinskimmel
#oncology #cancer #smallcelllungcancer

[Decera Clinical Insights @DeceraClinIns]

Join us Sept 21 as @CyrusKhann presents clinical efficacy and safety data supporting the use of a selective Bruton tyrosine kinase inhibitor for the treatment of previously untreated and R/R CLL. Claim your seat! https://t.co/lz8rvqXDhx #hematology #oncology

[Decera Clinical Insights @DeceraClinIns]

Join us September 14 as @OmarNadeemMD overviews "The Journey Through CAR-T Therapy: Design, Manufacturing, and Considerations for Physicians and Patients". Register Now! https://t.co/k7V7ibDfL1 #oncology #hematology

[Decera Clinical Insights @DeceraClinIns]

Join us on September 28 for targeting NSCLC with EGFR exon 20 insertions. Dr. @JSabari will discuss current treatment protocols. Register Now! https://t.co/4UlAYzGz2L #oncology #nsclc

[ClinicalXchange @ClinicalXchange]

We congratulate the NADIM II clinical study team for their great work. These data were also featured in a recent plenary session at the @IASLC conference. @ASCO
#nivolumab #NSCLC #ctDNA #lungcancer

[Daiichi Sankyo US @DaiichiSankyoUS]

We will be attending American Conference on Pharmacometrics (ACoP13) this October. We’re excited to meet fellow professionals who are dedicated to advancing the discipline of Pharmacometrics and broadening its impact. #PharmaCareers #DSProud

[ClinicalXchange @ClinicalXchange]

Congratulations to the TROPION-Lung02 study team for their recent presentation at the @IASLC conference.
#WCLC22 #LCSM #CALGB #oncology #NSCLC #LungCancer #clinicaltrials

[ClinicalXchange @ClinicalXchange]

Results from YESS study at recent @IASLC conference concluded that smokers receiving LHC in presence of co-located smoking cessation service experience quit rates considerably higher 3-months post-LHC.
https://t.co/SvgXf5ploX

#WCLC22 #LCSM #oncology #clinicaltrials

[Decera Clinical Insights @DeceraClinIns]

Join @OmarNadeemMD on August 31 for a concise and informative 30-minute webinar covering abstracts from the #IMS22 meeting on advances in chimeric antigen receptor T (CAR-T) cell therapy. Register Now! https://t.co/UPIt8Ez3yU #hematology #oncology

[ClinicalXchange @ClinicalXchange]

@ASCO Plenary Series Program: free, monthly online forum for latest oncology research. 9/16/22 3:00pm – 4:00pm will feature discussions on genetic testing for HRR & pathogenic germline variants in patients w/ lung cancer. @HosseinBorghaei Register at:
https://t.co/o88x7RPtw0

[ClinicalXchange @ClinicalXchange]

Results of phase 3 POLO trial in @ASCO JCO: Hazard Ratio numerically favored patients receiving Olaparib. Data confer clinically meaningful benefits incl. increased time off chemo & long-term survival in subset of patients. @UChicago Medicine

[ClinicalXchange @ClinicalXchange]

ICYMI: @ASCO Guidelines podcast @Jaiyesi1 @BeaumontHealth reviews first-, second- & third-line therapy in patients w/ stage IV NSCLC w/o driver alterations. Full guideline: https://t.co/8NHagtVinB.
https://t.co/ZY4Tdobqyr
#hematology #cancerresearch #oncology

[ClinicalXchange @ClinicalXchange]

Join @AlanTanMD for “Exploring I-O Therapies for the Treatment of Metastatic Melanoma,” a @ClinicalXchange webinar on Wed., 7/27,
12:15 - 12:45 pm ET. Details/reg: https://t.co/Otr77V6kKI @RushMedical @Alliance_org
#cancerresearch #oncology #clinicalresearch #clinicaltrials

[ClinicalXchange @ClinicalXchange]

On #IndependenceDay, consider oncology #clinicaltrials data independence. DCTs are more prevalent. What impacts are coming to clinical trial design & delivery? Are IRBs & IDMCs keeping pace w/ growth? Are new methods needed? Let us know in comments below. https://t.co/5tgOXNj2TI

[ClinicalXchange @ClinicalXchange]

#ASCO22 @MarinaGarassino poster “A randomized, double-blind, phase 3 trial of MK-7684A + chemotherapy versus pembrolizumab plus chemotherapy as first-line therapy for metastatic NSCLC: KeyVibe-007.” @UChicago @DanaFarber @Merck
https://t.co/Fv39TrRl7I

https://t.co/0tig2Jefwb